Top

Published in:

Open Access 01-07-2017

Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation

Authors: Louis S. Matza, Karen C. Chung, Katherine J. Kim, Trena M. Paulus, Evan W. Davies, Katie D. Stewart, Grace A. McComsey, Marshall W. Fordyce

Published in: Quality of Life Research | Issue 7/2017

Abstract

Purpose

Despite benefits of antiretroviral therapies (ART), people with HIV infection have increased risk of cardiovascular disease, kidney disease, and low bone mineral density. Some ARTs increase risk of these events. The purpose of this study was to examine patients’ perspectives of these risks and estimate health state utilities associated with these risks for use in cost-utility models.

Methods

Qualitative thematic analysis was conducted to examine messages posted to the POZ/AIDSmeds Internet community forums, focusing on bone, kidney, and cardiovascular side effects and risks of HIV/AIDS medications. Then, health state vignettes were drafted based on this qualitative analysis, literature review, and clinician interviews. The health states (representing HIV, plus treatment-related risks) were valued in time trade-off interviews with general population participants in the UK.

Results

Qualitative analysis of the Internet forums documented patient concerns about ART risks, as well as treatment decisions made because of these risks. A total of 208 participants completed utility interviews (51.4% female; mean age 44.6 years). The mean utility of the HIV health state (virologically suppressed, treated with ART) was 0.86. Adding a description of risk resulted in statistically significant disutility (i.e., utility decreases): renal risk (disutility = −0.02), bone risk (−0.03), and myocardial infarction risk (−0.05).

Conclusions

Patient concerns and treatment decisions were documented via qualitative analysis of Internet forum discussions, and the impact of these concerns was quantified in terms of health state utilities. The resulting disutilities may be useful for differentiating among ARTs in economic modeling of treatment for patients with HIV.

Available only for authorised users

De Cock, K. M., Jaffe, H. W., & Curran, J. W. (2012). The evolving epidemiology of HIV/AIDS. AIDS, 26(10), 1205–1213.CrossRefPubMed

UNAIDS. (2015). How AIDS changed everything—MDG6: 15 years, 15 lessons of hope from the AIDS response; 380; http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf. Accessed 17 Aug 2015.

World Health Organization (WHO). (Updated July 2015). HIV/AIDS Fact Sheet 2015. http://www.who.int/mediacentre/factsheets/fs360/en/. Accessed 17 Aug 2015.

Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., et al. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. The New England Journal of Medicine, 365(6), 493–505.CrossRefPubMedPubMedCentral

Nakagawa, F., Lodwick, R. K., Smith, C. J., Smith, R., Cambiano, V., Lundgren, J. D., et al. (2012). Projected life expectancy of people with HIV according to timing of diagnosis. AIDS, 26(3), 335–343.CrossRefPubMed

Palella, F. J. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. The New England Journal of Medicine, 338(13), 853–860.CrossRefPubMed

Peltzer, K., & Phaswana-Mafuya, N. (2008). The symptom experience of people living with HIV and AIDS in the Eastern Cape, South Africa. BMC Health Services Research, 8, 271.CrossRefPubMedPubMedCentral

Rao, D., Nainis, N., Williams, L., Langner, D., Eisin, A., & Paice, J. (2009). Art therapy for relief of symptoms associated with HIV/AIDS. AIDS Care, 21(1), 64–69.CrossRefPubMed

Durand, M., Sheehy, O., Baril, J. G., Lelorier, J., & Tremblay, C. L. (2011). Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. Journal of Acquired Immune Deficiency Syndromes, 57(3), 245–253.CrossRefPubMed

10.

Lang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., Simon, A., et al. (2010). Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Archives of Internal Medicine, 170(14), 1228–1238.CrossRefPubMed

11.

Worm, S. W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., et al. (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. The Journal of Infectious Diseases, 201(3), 318–330.CrossRefPubMed

12.

Bedimo, R., Maalouf, N. M., Zhang, S., Drechsler, H., & Tebas, P. (2012). Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS, 26(7), 825–831.CrossRefPubMed

13.

Martin, A., Bloch, M., Amin, J., Baker, D., Cooper, D. A., Emery, S., et al. (2009). Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clinical Infectious Diseases, 49(10), 1591–1601.CrossRefPubMed

14.

McComsey, G. A., Kitch, D., Daar, E. S., Tierney, C., Jahed, N. C., Tebas, P., et al. (2011). Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. The Journal of Infectious Diseases, 203(12), 1791–1801.CrossRefPubMedPubMedCentral

15.

Brennan, A., Evans, D., Maskew, M., Naicker, S., Ive, P., Sanne, I., et al. (2011). Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS, 25(13), 1603–1609.CrossRefPubMedPubMedCentral

16.

Cooper, R. D., Wiebe, N., Smith, N., Keiser, P., Naicker, S., & Tonelli, M. (2010). Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clinical Infectious Diseases, 51(5), 496–505.CrossRefPubMed

17.

Sax, P.E., Gallant, J.E., and Klotman, P.E. (2007). Renal safety of tenofovir disoproxil fumarate. AIDS Read, 17(2), 90–2, 99–104, C3.

18.

Foglia, E., Bonfanti, P., Rizzardini, G., Bonizzoni, E., Restelli, U., Ricci, E., et al. (2013). Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world. PLoS ONE, 8(2), e57777.CrossRefPubMedPubMedCentral

19.

Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, A. D., Cohen, C. J., Seage, G. R., et al. (2001). The cost effectiveness of combination antiretroviral therapy for HIV disease. The New England Journal of Medicine, 344(11), 824–831.CrossRefPubMed

20.

Ganguli, A., Wang, J., & Gourley, D. R. (2012). Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study. Research in Social and Administrative Pharmacy, 8(2), 157–165.CrossRefPubMed

21.

Maggiolo, F., Colombo, G. L., Di Matteo, S., Bruno, G. M., Astuti, N., Di Filippo, E., et al. (2015). Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Related Outcome Measures, 6, 53–60.PubMedPubMedCentral

22.

Rosen, S., Long, L., Fox, M., & Sanne, I. (2008). Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. Journal of Acquired Immune Deficiency Syndromes, 48(3), 334–344.CrossRefPubMed

23.

Sax, P. E., Losina, E., Weinstein, M. C., Paltiel, A. D., Goldie, S. J., Muccio, T. M., et al. (2005). Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. Journal of Acquired Immune Deficiency Syndromes, 39(1), 69–77.CrossRefPubMed

24.

Simpson, K. N., Luo, M. P., Chumney, E., Sun, E., Brun, S., & Ashraf, T. (2004). Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clinical Trials, 5(5), 294–304.CrossRefPubMed

25.

Brazier, J. R., Ratcliffe, J., Salomon, J. A., & Tsuchiya, A. (2007). Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press.

26.

Feeny, D. (2005). Preference-based measures: utility and quality-adjusted life years. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials (pp. 405–431). New York: Oxford University Press.

27.

Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. Journal of Health Economics, 5(1), 1–30.CrossRefPubMed

28.

Bayoumi, A. M., & Redelmeier, D. A. (1999). Economic methods for measuring the quality of life associated with HIV infection. Quality of Life Research, 8(6), 471–480.CrossRefPubMed

29.

Honiden, S., Sundaram, V., Nease, R. F., Holodniy, M., Lazzeroni, L. C., Zolopa, A., et al. (2006). The effect of diagnosis with HIV infection on health-related quality of Life. Quality of Life Research, 15(1), 69–82.CrossRefPubMed

30.

Kauf, T. L., Roskell, N., Shearer, A., Gazzard, B., Mauskopf, J., Davis, E. A., et al. (2008). A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value in Health, 11(7), 1144–1153.CrossRefPubMed

31.

Lara, A. M., Wakholi, B. N., Kasirye, A., Munderi, P., Watera, C., Lalloo, D. G., et al. (2008). Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans. AIDS, 22(Suppl 1), 123–130.CrossRef

32.

Mrus, J. M., Yi, M. S., Freedberg, K. A., Wu, A. W., Zackin, R., Gorski, H., et al. (2003). Utilities derived from visual analog scale scores in patients with HIV/AIDS. Medical Decision Making, 23(5), 414–421.CrossRefPubMed

33.

Owens, D. K., Cardinalli, A. B., & Nease, R. F. Jr. (1997). Physicians’ assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Quality of Life Research, 6(1), 77–86.CrossRefPubMed

34.

Revicki, D. A., Wu, A. W., & Murray, M. I. (1995). Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Medical Care, 33(4 Suppl), AS173–A82.PubMed

35.

Sakthong, P., Schommer, J. C., Gross, C. R., Prasithsirikul, W., & Sakulbumrungsil, R. (2009). Health utilities in patients with HIV/AIDS in Thailand. Value in Health, 12(2), 377–384.CrossRefPubMed

36.

Schackman, B. R., Goldie, S. J., Freedberg, K. A., Losina, E., Brazier, J., & Weinstein, M. C. (2002). Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Medical Decision Making, 22(1), 27–38.CrossRefPubMed

37.

Tengs, T. O., & Lin, T. H. (2002). A meta-analysis of utility estimates for HIV/AIDS. Medical Decision Making, 22(6), 475–481.CrossRefPubMed

38.

Tran, B. X., Nguyen, L. H., Ohinmaa, A., Maher, R. M., Nong, V. M., & Latkin, C. A. (2015). Longitudinal and cross sectional assessments of health utility in adults with HIV/AIDS: a systematic review and meta-analysis. BMC Health Services Research, 15, 7.CrossRefPubMedPubMedCentral

39.

Humphrey, L., Mahapatra, R., Trundell, D., Kitchen, H. (2015, 7–11 November 2015). Patient-reported outcomes & patient preference research issues: blog it, tweet it, like it, or bin it? The Role of Social Media Data in Patient-reported Outcomes Research (IP5). Issue Panel: Sesion I at ISPOR 18th Annual European Congress. Milan, Italy.

40.

NICE (National Institute for Health and Care Excellence) (2013). Process and methods guides: Guide to the methods of technology appraisal 2013. London: NICE.

41.

Auerbach, C. F., & Silverstein, L. B. (2003). Qualitative data: an introduction to coding and analysis. New York: NYU Press.

42.

Boyatzis, R. E. (1998). Transforming qualitative information: thematic analysis and code development. Thousand Oaks, CA: Sage Publications.

43.

Gibson, W. J., & Brown, A. (2009). Working with qualitative data. London: Sage Publications.CrossRef

44.

Chiou, P. Y., Kuo, B. I., Lee, M. B., Chen, Y. M., Chuang, P., & Lin, L. C. (2006). A programme of symptom management for improving quality of life and drug adherence in AIDS/HIV patients. Journal of Advanced Nursing, 55(2), 169–179.CrossRefPubMed

45.

Volberding, P. A., & Deeks, S. G. (2010). Antiretroviral therapy and management of HIV infection. Lancet, 376(9734), 49–62.CrossRefPubMed

46.

Matza, L. S., Stewart, K. D., Gandra, S. R., Delio, P. R., Fenster, B. E., Davies, E. W., et al. (2015). Acute and chronic impact of cardiovascular events on health state utilities. BMC Health Services Research, 15, 173.CrossRefPubMedPubMedCentral

47.

Rowen, D., Brazier, J., Tsuchiya, A., Young, T., & Ibbotson, R. (2012). It’s all in the name, or is it? The impact of labeling on health state values. Medical Decision Making, 32(1), 31–40.CrossRefPubMed

48.

Arnesen, T., & Trommald, M. (2005). Are QALYs based on time trade-off comparable? A systematic review of TTO methodologies. Health Economics, 14(1), 39–53.CrossRefPubMed

49.

Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed

50.

Dolan, P., Gudex, C., Kind, P., & Williams, A. (1996). The time trade-off method: results from a general population study. Health Economics, 5(2), 141–154.CrossRefPubMed

51.

CADTH (Canadian Agency for Drugs and Technologies in Health). (2006). Guidelines for the economic evaluation of health technologies: Canada, Ottawa: CADTH.

52.

PBAC (Pharmaceutical Benefits Advisory Committee). (2013). Guidelines for preparing submissions to PBAC, Version 4.4. Canberra: Australian Government Department of Health, PBAC.

53.

Matza, L. S., Sapra, S. J., Dillon, J. F., Kalsekar, A., Davies, E. W., Devine, M. K., et al. (2015). Health state utilities associated with attributes of treatments for hepatitis C. The European Journal of Health Economics, 16(9), 1005–1018.CrossRefPubMed

54.

Rowen, D., & Brazier, J. (2011). Health Utility Measurement. In S. Glied & P. Smith (Eds.), The oxford handbook of health economics (pp. 788–813). New York: Oxford University Press.

55.

Matza, L. S., Chung, K., Van Brunt, K., Brazier, J. E., Braun, A., Currie, B., et al. (2014). Health state utilities for skeletal-related events secondary to bone metastases. The European Journal of Health Economics, 15(1), 7–18.CrossRefPubMed

56.

Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., et al. (2005). The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Annals of Oncology, 16(4), 579–584.CrossRefPubMed

57.

Davies, E. W., Matza, L. S., Worth, G., Feeny, D. H., Kostelec, J., Soroka, S., et al. (2015). Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health and Quality of Life Outcomes, 13, 90.CrossRefPubMedPubMedCentral

58.

Liem, Y. S., Bosch, J. L., & Hunink, M. G. (2008). Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value in Health, 11(4), 733–741.CrossRefPubMed

59.

Wyld, M., Morton, R. L., Hayen, A., Howard, K., & Webster, A. C. (2012). A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Medicine, 9(9), e1001307.CrossRefPubMedPubMedCentral

60.

Lewis, E. F., Li, Y., Pfeffer, M. A., Solomon, S. D., Weinfurt, K. P., Velazquez, E. J., et al. (2014). Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT stud (valsartan in acute myocardial infarction). JACC Heart Fail, 2(2), 159–165.CrossRefPubMed

61.

Smith, D. W., Davies, E. W., Wissinger, E., Huelin, R., Matza, L. S., & Chung, K. (2013). A systematic literature review of cardiovascular event utilities. Expert Review of Pharmacoeconomics and Outcomes Research, 13(6), 767–790.CrossRefPubMed

62.

Preece, J., Nonnecke, B., & Andrews, D. (2004). The top five reasons for lurking: improving community experiences for everyone. Computers in Human Behavior, 20(2), 201–223.CrossRef

63.

DAD Study Group, et al. (2007). Class of antiretroviral drugs and the risk of myocardial infarction. The New England Journal of Medicine, 356(17), 1723–1735.CrossRef

64.

DAD Study Group, et al. (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 371(9622), 1417–1426.CrossRef

65.

Obel, N., Farkas, D. K., Kronborg, G., Larsen, C. S., Pedersen, G., Riis, A., et al. (2010). Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Medicine, 11(2), 130–136.CrossRefPubMed

66.

Palella, F. J. Jr., Althoff, K. N., Moore, R., Zhang, J., Kitahata, M., Gange, S. J., et al. (2015, February 23–26). Abacavir use and risk for myocardial infarction in the NA-ACCORD. Poster presented at Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA.

67.

Sabin, C. A., Reiss, P., Ryom, L., De Wit, S., Kirk, O., Weber, R., et al. (2014, March 3–6). Is there continued evidence for an association between abacavir and myocardial infarction risk? Poster presented at 21st Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA

68.

Cruciani, M., Zanichelli, V., Serpelloni, G., Bosco, O., Malena, M., Mazzi, R., et al. (2011). Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS, 25(16), 1993–2004.CrossRefPubMed

69.

Ding, X., Andraca-Carrera, E., Cooper, C., Miele, P., Kornegay, C., Soukup, M., et al. (2012). No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. Journal of Acquired Immune Deficiency Syndromes, 61(4), 441–447.CrossRefPubMed

70.

Ribaudo, H. J., Benson, C. A., Zheng, Y., Koletar, S. L., Collier, A. C., Lok, J. J., et al. (2011). No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clinical Infectious Diseases, 52(7), 929–940.CrossRefPubMedPubMedCentral

71.

Fux, C. A., Simcock, M., Wolbers, M., Bucher, H. C., Hirschel, B., Opravil, M., et al. (2007). Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral Therapy, 12(8), 1165–1173.PubMed

72.

Gallant, J. E., Parish, M. A., Keruly, J. C., & Moore, R. D. (2005). Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clinical Infectious Diseases, 40(8), 1194–1198.CrossRefPubMed

73.

Nishijima, T., Kawasaki, Y., Tanaka, N., Mizushima, D., Aoki, T., Watanabe, K., et al. (2014). Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS, 28(13).

Title: Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation
Authors: Louis S. Matza
Karen C. Chung
Katherine J. Kim
Trena M. Paulus
Evan W. Davies
Katie D. Stewart
Grace A. McComsey
Marshall W. Fordyce
Publication date: 01-07-2017
Publisher: Springer International Publishing
Published in: Quality of Life Research / Issue 7/2017
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-017-1519-3

At a glance: The STEP trials

Springer Medicine

Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2017

Examining health-related quality of life patterns in women with breast cancer

Comparing effects between music intervention and aromatherapy on anxiety of patients undergoing mechanical ventilation in the intensive care unit: a randomized controlled trial

Psychometric evaluation of the pediatric and parent-proxy Patient-Reported Outcomes Measurement Information System and the Neurology and Traumatic Brain Injury Quality of Life measurement item banks in pediatric traumatic brain injury

Validation of the PROMIS® measures of self-efficacy for managing chronic conditions

Prospective associations of exercise and depressive symptoms in older adults: the role of apolipoprotein E4

Changes in quality of life from a homelessness intervention: true change, response shift, or random variation